Publications of Christine GENNIGENS
Bookmark and Share    
Full Text
See detailPhase Ib/II trial of tisotumab vedotin+/- bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024)
Vergote, Ignace; Concin, Nicole; Mirza Raza, Mansoor et al

Poster (2020, May)

Detailed reference viewed: 39 (1 ULiège)
Full Text
See detailAn update on the management of metastatic clear-cell renal cell carcinoma: the BSMO expert panel recommendations
Delafontaine, B; De Backer, C; Beuselinck, B et al

in Belgian Journal of Medical Oncology (2020), 14(2),

Detailed reference viewed: 29 (1 ULiège)
Full Text
See detailCorrelation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy.
Gennigens, Christine ULiege; DE CUYPERE, Marjolein ULiege; SEIDEL, Laurence ULiege et al

in Cancer Medicine (2020)

BACKGROUND: Hemoglobin (Hb), white blood cell (WBC), and polymorphonuclear neutrophil (PMN) blood counts may be correlated with outcomes in patients with locally advanced cervical cancer. METHODS: Hb, WBC ... [more ▼]

BACKGROUND: Hemoglobin (Hb), white blood cell (WBC), and polymorphonuclear neutrophil (PMN) blood counts may be correlated with outcomes in patients with locally advanced cervical cancer. METHODS: Hb, WBC, and PMN counts were measured at diagnosis and during concomitant cisplatin-based chemoradiotherapy (CCRT) in a retrospective sample of 103 patients between 2010 and 2017. Red blood cell (RBC) transfusions were also recorded. The associations between hematological variables and patient overall survival (OS) and recurrence-free survival (RFS) were assessed by Cox regression models. RESULTS: The 3-year OS and RFS rates were 81.4% and 76.8%, respectively. In addition to tumor size and smoking, OS and RFS were found to be significantly associated with changes in WBC and PMN counts from the first to the last cisplatin cycle. Hb count throughout the treatment and RBC transfusions were not predictive of outcome. CONCLUSIONS: This study found no association between Hb count or RBC transfusions and outcome. The daily practice of maintaining the Hb count above 12 g/dL during CCRT should be weighed against the potential risks of transfusions. Drops in WBC and PMN counts during treatment positively impacted OS and RFS and could, therefore, serve as biomarkers during CCRT to adapt the follow-up and consider the need for adjuvant systemic treatments. [less ▲]

Detailed reference viewed: 22 (4 ULiège)
Full Text
See detailTumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer.
DE CUYPERE, Marjolein ULiege; Lovinfosse, Pierre; Gennigens, Christine ULiege et al

in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020), 0

OBJECTIVE: The aim of this study was to investigate the prognostic value of metabolic parameters obtained at pretreatment [(18)F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ... [more ▼]

OBJECTIVE: The aim of this study was to investigate the prognostic value of metabolic parameters obtained at pretreatment [(18)F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([(18)F]FDG PET/CT) in patients with locally advanced cervical cancer. We hypothesize that these metabolic parameters could optimize the treatment decision and thus favor the outcome of patients suffering locally advanced cervical cancer. METHODS: Patients with locally advanced cervical cancer underwent pretreatment PET/CT. Standard uptake values (maximum, mean, peak), metabolic tumor volume, and total lesion glycolysis were measured in the tumor and in the hypermetabolic pelvic lymph nodes. The relationship between clinical, pathological, and PET/CT metabolic parameters with recurrence-free survival and overall survival was assessed by Cox regression analysis. RESULTS: 115 patients with a median age of 52 years (range 23-77) presented with locally advanced cervical cancer. After a mean follow-up of 33.0 months after initiation of therapy, 26 patients (22.6%) recurred of which 17 patients had distant metastasis; 18 (15.7%) patients died. Recurrence-free survival at 2 and 5 years was 79.2% and 72.2%, respectively. The total lesion glycolysis of the tumor and the delay between diagnosis and treatment were significantly associated with recurrence-free survival in the multivariate analysis (HR 1.00, p=0.004, and HR 2.04, p=0.02, respectively). Only the total lesion glycolysis of the tumor ≥373.54 (HR 2.49, 95% CI 1.15 to 5.38; p=0.02) remained significant after log rank testing. Overall survival at 2 and 5 years was 91.7% and 68.8%, respectively. The number of PET-positive pelvic lymph nodes was the only independent prognostic factor for overall survival in the multivariate analysis (HR 1.43, 95% CI 1.13 to 1.81; p=0.003). CONCLUSION: Tumor total lesion glycolysis and the number of positive pelvic lymph nodes on pretreatment PET/CT appear to be independent prognostic factors for recurrence and survival in patients with locally advanced cervical cancer. This may help to select patients who may benefit from therapeutic optimization and closer surveillance. [less ▲]

Detailed reference viewed: 20 (3 ULiège)
Full Text
See detailTreatment algorithm in patients with ovarian cancer.
Vergote, I.; Denys, H.; De Greve, J. et al

in Facts, views & vision in ObGyn (2020), 12(3), 227-239

Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian ... [more ▼]

Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium. [less ▲]

Detailed reference viewed: 23 (2 ULiège)
Full Text
See detailTisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong, David S.; Concin, Nicole; Vergote, Ignace et al

in Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

PURPOSE: Tissue factor (TF) is a potential target in cervical cancer as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody ... [more ▼]

PURPOSE: Tissue factor (TF) is a potential target in cervical cancer as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody-drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase 1/2 study (NCT02001623). EXPERIMENTAL DESIGN: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. RESULTS: Of the 55 patients, 51% had received >/=2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab+doublet chemotherapy. 51% of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% (95% confidence interval [CI]: 13%-37%). Median duration of response (DOR) was 4.2 months (range: 1.0+-9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%-43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%-35%), median DOR of 6.0 months (range: 1.0+-9.7), and 6-month PFS rate of 40% (95% CI: 24%-55%). TF expression was confirmed in most patients; no significant association with response was observed. CONCLUSIONS: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer. [less ▲]

Detailed reference viewed: 29 (4 ULiège)
Full Text
See detailState of the art in the treatment of soft tissue sarcomas
GENNIGENS, Christine ULiege; JERUSALEM, Guy ULiege

in Belgian Journal of Medical Oncology (2019), 13(6), 227-233

Detailed reference viewed: 42 (7 ULiège)
Full Text
See detailAdded value of para-aortic surgical staging compared to (18)F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study.
DE CUYPERE, Marjolein ULiege; LOVINFOSSE, Pierre ULiege; GOFFIN, Frédéric ULiege et al

in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2019)

OBJECTIVE: Extended field chemoradiation is recommended for patients with locally advanced cervical cancer (LACC) and para-aortic lymph node (PALN) metastases. The radiation planning may be based on PET ... [more ▼]

OBJECTIVE: Extended field chemoradiation is recommended for patients with locally advanced cervical cancer (LACC) and para-aortic lymph node (PALN) metastases. The radiation planning may be based on PET/CT while others recommend to rely on surgical staging. We report the rate of patients for whom the radiation field defined on PET/CT was modified by the histological PALN status. METHODS: Between March 2010 and December 2016, 168 consecutive patients with LACC underwent a pre-therapeutic PET/CT and PALN dissection. The data were reviewed retrospectively. The diagnostic performance of the PET/CT for definition of PALN status was calculated. We determined the percentage of patients for whom PALN dissection altered the external beam radiotherapy (EBRT) field defined on the PET/CT basis. RESULTS: Of 151 patients with negative PALNs on PET/CT, 26 had histological PALN metastases. Of 17 patients with positive PALNs on PET/CT, 9 were negative on histology of which 7 were located in the common iliac region. Sensitivity, specificity, positive and negative predictive value of PET/CT were 23.5, 93.3, 47.1 and 82.8% respectively. In total, 35 out of 168 patients underwent EBRT - field adaptation (pelvic vs extended field). The rate of radiation field modification (27,7%) was particularly high in the subgroup of patients with metastatic pelvic lymph nodes (PLNs) on PET/CT. CONCLUSION: Para-aortic surgical staging contributes significantly to individualize the radiation treatment of patients with LACC, particularly for those with positive PLNs at PET/CT. Indication of surgical staging deserves particular attention when the PET/CT suggests positive LNs in the common iliac region. [less ▲]

Detailed reference viewed: 31 (10 ULiège)
Full Text
See detailA phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer : updated analysis of full cervical expansion cohort
Concin, Nicole; Vergote, Ignace; Lassen, Ulrik Niels et al

Poster (2018, October 20)

Detailed reference viewed: 21 (3 ULiège)
Full Text
See detailLeptomeningeal carcinomatosis from solid tumours : a systematic review of the literature
FRERES, Pierre ULiege; GENNIGENS, Christine ULiege; Martin, Didier ULiege et al

in Belgian Journal of Medical Oncology (2017), 11

Detailed reference viewed: 37 (0 ULiège)
Full Text
See detailAdipsic diabetes insipidus revealing a bifocal intracranial germinoma
KREUTZ, Julie ULiege; Potorac, Iulia ULiege; LUTTERI, Laurence ULiege et al

in Annales d'Endocrinologie (2017)

Abstract Adipsic diabetes insipidus is a rare complication of intracranial tumors in which impaired antidiuretic hormone secretion is associated with the loss of thirst sensation. Here, we present the ... [more ▼]

Abstract Adipsic diabetes insipidus is a rare complication of intracranial tumors in which impaired antidiuretic hormone secretion is associated with the loss of thirst sensation. Here, we present the case of a patient with bifocal intracranial germinoma, diagnosed due to symptoms mainly caused by adipsic diabetes insipidus. This is, to our knowledge, the first case of adipsic diabetes insipidus revealing an intracranial germinoma reported in the literature. We describe the diagnostic procedures and the three-year follow-up of this patient. Management of intracranial germ-cell tumors is made complex by the wide range of histological features. Although germinomas have a generally better prognosis than most nongerminomatous tumors, they can have severe or even life-threatening presentations. Adipsic diabetes insipidus is one such severe presentation and its rarity can make it difficult to recognize and manage. Awareness of this potential entity is therefore important for clinical practice. Le diabète insipide adipsique est une des rares complications des tumeurs intracrâniennes. Il associe une baisse de la sécrétion d’hormone antidiurétique à une perte de la sensation de soif et ilsignale souvent la présence d’une lésion qui atteint ou envahit l’hypothalamus. Nous présentons le cas d’une patiente avec un germinome intracrânien bifocal diagnostiqué devant un tableau de diabète insipide adipsique. À notre connaissance, il s’agit du premier cas de la littérature d’un diabète insipide révélant un germinome intracrânien. La prise en charge des tumeurs germinales intracrâniennes est complexe du fait des phénotypes histologiques divers. Bien que les germinomes ont généralement un meilleur pronostic que les tumeurs non-germinomateuses, ils peuvent avoir des présentations sévères. Le diabète insipide adipsique est une de ces présentations sévères et sa rareté peut rendre son diagnostic et sa prise en charge difficiles. La reconnaissance de cette entité potentielle est, dès lors, importante pour la pratique clinique [less ▲]

Detailed reference viewed: 99 (22 ULiège)
Full Text
See detailA phase IIA study of tisotumab vedotin (Humax - TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
Vergote, I; Concin, N; Dean, E et al

in Annals of Oncology (2017), 28(suppl 5), 331

Detailed reference viewed: 93 (3 ULiège)
Full Text
See detailLe carcinome de site primitif inconnu, une entité pas si rare ...
GONNE, Elodie ULiege; COLLIGNON, Joëlle ULiege; JERUSALEM, Guy ULiege et al

in Revue Médicale de Liège (2016), 71(10), 449-454

Les carcinomes de site primitif inconnu ou CaPI, forment un groupe d'entités pathologiques très hétérogènes de par leurs modes de révélation et leurs présentations cliniques. Le CaPI se définit par une ... [more ▼]

Les carcinomes de site primitif inconnu ou CaPI, forment un groupe d'entités pathologiques très hétérogènes de par leurs modes de révélation et leurs présentations cliniques. Le CaPI se définit par une tumeur épithéliale maligne, d'emblée métastatique, dont le site initial reste occulte au terme du bilan pré-thérapeutique exhaustif. Il représente 3 à 5% des tumeurs solides malignes de l'adulte. Son pronostic est sombre avec médiane de survie allant de 6 à 10 mois. La thérapeutique sera fonction de l'histologie tumorale, de la localisation métastatique et de la suspicion d'origine du primitif. En présence d'une néoplasie localisée, une prise en charge chirurgicale accompagnée ou non d'une radiothérapie sera proposée; en cas de dissémination métastatique multiple, une chimiothérapie systémique à base de sels de platine est recommandée. L'espoir réside dans l'analyse du profil moléculaire, afin de définir avec précision l'origine tumorale primitive et d'offrir la thérapeutique la mieux adaptée possible. [less ▲]

Detailed reference viewed: 104 (4 ULiège)
Full Text
See detailPrimary osteosarcoma of the breast : a case report
Crevecoeur, Julie; Jossa, Véronique; GENNIGENS, Christine ULiege et al

in Clinical Case Reports (2015)

Detailed reference viewed: 43 (2 ULiège)